The COVID-19 pandemic is a global emergency. Identifying populations who are at risk of severe complications is crucial in developing special measures to prevent or reduce severe illness and mortality in vulnerable patients. Emerging evidence indicates that alpha1-proteinase inhibitor might inhibit infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). α1-Antitrypsin
We were pleased to announce back in August 2020 that the first person was dosed with ZF874, a potential treatment for alpha-1-antitrypsin deficiency. Then on the 24th September we published the details for HMR who are running the trail on behalf of Z Factor, asking for PiMZ people to help.